Investor's Business Daily on MSN20h
Novo Nordisk Inks Its Second Big Obesity Deal In A Week — And It's Not For A GLP-1
Novo Nordisk stock slipped 1.2% to 69.30. Novo Nordisk Is On A Licensing Spree. This is the second big weight-loss deal from Novo ...
Healio1d
Novel islet cell therapy eliminates severe hypoglycemia, cuts HbA1c in type 1 diabetes
A novel islet cell therapy delivered through a single infusion lowered HbA1c and eliminated severe hypoglycemia events for ...
Lexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851
Lexicon is eligible to receive upfront and near-term milestone payments of up to $75 million. In total, Lexicon will be eligible to receive $1 billion in upfront and potential development, regulatory ...
Novo Nordisk inks licensing pact with Lexicon for obesity candidate
Lexicon Pharmaceuticals (LXRX) stock soars as the company inks a licensing deal worth up to $1B with Novo Nordisk (NVO) for ...
BoFA says Novo Nordisk may miss Q1 expectations as Wegovy, Ozempic sales lag
Bank of America analysts on Friday said Novo Nordisk may miss first-quarter expectations, as sales of its blockbuster Wegovy ...
STAT1d
Novo Nordisk sets sights on new type of oral obesity drug
Novo Nordisk has licensed an oral obesity drug that works via an uncommon mechanism and may help patients maintain their ...
Fierce Biotech1d
Novo inks $1B biobucks Lexicon obesity deal after seeing preclinical prospect shine with semaglutide
Lexicon Pharmaceuticals’ pursuit of the last word in obesity candidates has attracted Novo Nordisk. | Lexicon Pharmaceuticals ...